330 filings
Page 7 of 17
8-K
ur6aqobr58lt 5i0g9fy
11 May 15
Provides Business Update Including Phase 2 NASH Program
12:00am
8-K
fqij 012h6qd4xa0
18 Mar 15
Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update
12:00am
8-K
0ga5 wurzqepkzna
12 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
gmvwif
24 Feb 15
Galectin Therapeutics Announces Details of the Design of its Phase 2 Program with GR-MD-02
12:00am
8-K
uhhyn0kr
24 Feb 15
Regulation FD Disclosure
12:00am
8-K
i6ss5gfvjx
7 Jan 15
This presentation contains, in addition to historical information, forward-looking statements within the meaning
12:00am
8-K
zyomkbp7
7 Jan 15
Regulation FD Disclosure
12:00am
8-K
asgiqqlhu0l z5exq
12 Dec 14
Departure of Directors or Certain Officers
12:00am
8-K
p71a9
10 Nov 14
Phase 1 Clinical Trial Results Of GR-MD-02, A
12:00am
8-K
j105raa
10 Nov 14
Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company’s Development Program
12:00am
8-K
idwrf7 jktm9k8jztk
24 Sep 14
Departure of Directors or Certain Officers
12:00am
8-K
gne 69ifx91h9
15 Sep 14
Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy
12:00am
8-K
c8ahvc i6i
12 Sep 14
Other Events
12:00am
8-K
lns1otnlx
7 Aug 14
Galectin Therapeutics Reports Second Quarter 2014 Financial Results
12:00am
8-K
xcvi76xdl2 kwiu
5 Aug 14
Regulation FD Disclosure
12:00am
8-K
quyruj1aqqnb0mowkt
29 Jul 14
Results of Second Cohort
12:00am
8-K
50ze 7he5j
22 Jul 14
Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical
12:00am
8-K
fgalp1mh
28 May 14
Galectin Therapeutics Receives U.S. Patent for GR-MD-02
12:00am
8-K
5zyndhkbzph2h45r
20 May 14
Departure of Directors or Certain Officers
12:00am
8-K
0olvnifz
16 May 14
Submission of Matters to a Vote of Security Holders
12:00am